JP2023500707A - 炎症を特徴とする皮膚科状態の治療に使用するためのｉｒａｋ４阻害剤を含む局所用組成物 - Google Patents

炎症を特徴とする皮膚科状態の治療に使用するためのｉｒａｋ４阻害剤を含む局所用組成物 Download PDF

Info

Publication number
JP2023500707A
JP2023500707A JP2022526059A JP2022526059A JP2023500707A JP 2023500707 A JP2023500707 A JP 2023500707A JP 2022526059 A JP2022526059 A JP 2022526059A JP 2022526059 A JP2022526059 A JP 2022526059A JP 2023500707 A JP2023500707 A JP 2023500707A
Authority
JP
Japan
Prior art keywords
group
optionally substituted
methyl
aromatic heterocyclic
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022526059A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021092239A5 (https=
JP2023500707A5 (https=
Inventor
ジェイミー エル． ハーデン
ハンス イー． ジェイ． ホフランド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermira Inc
Original Assignee
Dermira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermira Inc filed Critical Dermira Inc
Publication of JP2023500707A publication Critical patent/JP2023500707A/ja
Publication of JPWO2021092239A5 publication Critical patent/JPWO2021092239A5/ja
Publication of JP2023500707A5 publication Critical patent/JP2023500707A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
JP2022526059A 2019-11-05 2020-11-05 炎症を特徴とする皮膚科状態の治療に使用するためのｉｒａｋ４阻害剤を含む局所用組成物 Ceased JP2023500707A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962931132P 2019-11-05 2019-11-05
US62/931,132 2019-11-05
US202063046143P 2020-06-30 2020-06-30
US63/046,143 2020-06-30
PCT/US2020/059200 WO2021092239A1 (en) 2019-11-05 2020-11-05 Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation

Publications (3)

Publication Number Publication Date
JP2023500707A true JP2023500707A (ja) 2023-01-10
JPWO2021092239A5 JPWO2021092239A5 (https=) 2023-12-15
JP2023500707A5 JP2023500707A5 (https=) 2023-12-15

Family

ID=73654894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526059A Ceased JP2023500707A (ja) 2019-11-05 2020-11-05 炎症を特徴とする皮膚科状態の治療に使用するためのｉｒａｋ４阻害剤を含む局所用組成物

Country Status (9)

Country Link
US (1) US20230125380A1 (https=)
EP (1) EP4054573A1 (https=)
JP (1) JP2023500707A (https=)
CN (2) CN118806758A (https=)
AU (1) AU2020380921A1 (https=)
BR (1) BR112022008610A2 (https=)
CA (1) CA3159624A1 (https=)
IL (1) IL292689A (https=)
WO (1) WO2021092239A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3186630A1 (en) * 2020-06-30 2022-01-06 Dermira, Inc. Irak4 inhibitors and topical uses thereof
CN118530374B (zh) * 2023-06-02 2025-11-04 东北农业大学 犬成纤维细胞生长因子21融合蛋白制备及其在治疗特应性皮炎中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535772A (ja) * 2013-11-08 2016-11-17 武田薬品工業株式会社 自己免疫疾患治療のためのピラゾール
WO2017205762A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
JP2018524372A (ja) * 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3727428A1 (en) * 2017-12-20 2020-10-28 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CA3186630A1 (en) * 2020-06-30 2022-01-06 Dermira, Inc. Irak4 inhibitors and topical uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535772A (ja) * 2013-11-08 2016-11-17 武田薬品工業株式会社 自己免疫疾患治療のためのピラゾール
JP2018524372A (ja) * 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物
WO2017205762A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase

Also Published As

Publication number Publication date
AU2020380921A1 (en) 2022-05-26
US20230125380A1 (en) 2023-04-27
CN114929223A (zh) 2022-08-19
IL292689A (en) 2022-07-01
EP4054573A1 (en) 2022-09-14
CA3159624A1 (en) 2021-05-14
CN118806758A (zh) 2024-10-22
BR112022008610A2 (pt) 2022-08-09
WO2021092239A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
ES2723876T3 (es) Nuevos derivados de pirazol
CN102046176B (zh) 5-ht3受体调节剂、其制备方法和用途
JP2021054843A (ja) トロポミオシン関連キナーゼ（ｔｒｋ）阻害剤
HK1252318A1 (zh) 抗菌治疗剂和预防剂
TW201831486A (zh) Ｐｄｅ２抑制劑
CN107531696B (zh) 作为nmda受体调节剂的吡啶并嘧啶酮类及它们的用途
CN113679717A (zh) 用于抑制肌成束蛋白的方法
WO2020156189A1 (zh) 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途
RU2667058C2 (ru) Ингибиторы фермента фосфодиэстеразы 10
JP2023500707A (ja) 炎症を特徴とする皮膚科状態の治療に使用するためのｉｒａｋ４阻害剤を含む局所用組成物
WO2013002365A1 (ja) 止痒剤
TW202016116A (zh) 作為a2a受體拮抗劑的吡唑並三唑並嘧啶衍生物
US20250017937A1 (en) Mglu2/3 antagonists for the treatment of intellectual disabilities
JP7813733B2 (ja) Ｉｒａｋ４阻害剤及びそれらの局所的使用方法
CN115844903A (zh) 白桦醇衍生物在制备抑制细菌药物中的用途
CN117327140B (zh) 一种具备抑制细菌用途的白桦脂酸衍生物
US20190337956A1 (en) Neuroactive compounds and methods of using same
AU2024225907A1 (en) Hydroxyalkyl and methoxyalkyl tryptamines
WO2017011445A1 (en) Heteroaryl carbonitriles for the treatment of disease
CN120842199A (zh) 一种双季铵盐化合物及其在医药上的应用
EA042675B1 (ru) Лиганд рецептора гамк-а
HK1227395A1 (en) Mglu2/3 antagonists for the treatment of intellectual disabilities

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220610

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250521

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250718

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20251027